A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.
Study Type
OBSERVATIONAL
Enrollment
212
No intervention other than routine medical care
Research Site
Tucson, Arizona, United States
Research Site
Duarte, California, United States
Treatment patterns in patients with Ph- R/R ALL
Time frame: 86 months
Drug utilization in patients with Ph- R/R ALL
Time frame: 86 months
Healthcare resource utilization in patients with Ph- R/R ALL
Time frame: 86 months
Receipt of allogeneic stem cell transplantation following salvage treatment
Time frame: 86 Months
Incidence of selected adverse events including cytokine release syndrome, neurologic events, any events resulting in hospitalizations, and other serious adverse events.
Time frame: 86 Months
Best response to salvage treatment (chemotherapy or blinatumomab) within 8 weeks and within 12 weeks of initiation of salvage treatment.
Time frame: 12 Weeks
MRD status within 12 weeks of initiation of salvage treatment
Time frame: 12 Weeks
Overall survival from the time of initiation of salvage treatment
Time frame: 86 Months
RFS from time remission achieved with salvage treatment
Time frame: 86 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Los Angeles, California, United States
Research Site
Chicago, Illinois, United States
Research Site
Ames, Iowa, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Baltimore, Maryland, United States
Research Site
Baltimore, Maryland, United States
Research Site
Detroit, Michigan, United States
Research Site
Hackensack, New Jersey, United States
...and 9 more locations